BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gangoso E, Southgate B, Bradley L, Rus S, Galvez-Cancino F, McGivern N, Güç E, Kapourani CA, Byron A, Ferguson KM, Alfazema N, Morrison G, Grant V, Blin C, Sou I, Marques-Torrejon MA, Conde L, Parrinello S, Herrero J, Beck S, Brandner S, Brennan PM, Bertone P, Pollard JW, Quezada SA, Sproul D, Frame MC, Serrels A, Pollard SM. Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion. Cell 2021;184:2454-2470.e26. [PMID: 33857425 DOI: 10.1016/j.cell.2021.03.023] [Cited by in Crossref: 71] [Cited by in F6Publishing: 76] [Article Influence: 71.0] [Reference Citation Analysis]
Number Citing Articles
1 Mundt S, Greter M, Becher B. The CNS mononuclear phagocyte system in health and disease. Neuron 2022;110:3497-3512. [DOI: 10.1016/j.neuron.2022.10.005] [Reference Citation Analysis]
2 Ferguson KM, Blin C, Alfazema N, Gangoso E, Pollard SM, Marques-torrejon MA. Lrig1 regulates the balance between proliferation and quiescence in glioblastoma stem cells. Front Cell Dev Biol 2022;10. [DOI: 10.3389/fcell.2022.983097] [Reference Citation Analysis]
3 Richard Q, Laurenge A, Mallat M, Sanson M, Castro-Vega LJ. New insights into the Immune TME of adult-type diffuse gliomas. Curr Opin Neurol 2022. [PMID: 36226710 DOI: 10.1097/WCO.0000000000001112] [Reference Citation Analysis]
4 Chen HM, Nikolic A, Singhal D, Gallo M. Roles of Chromatin Remodelling and Molecular Heterogeneity in Therapy Resistance in Glioblastoma. Cancers (Basel) 2022;14:4942. [PMID: 36230865 DOI: 10.3390/cancers14194942] [Reference Citation Analysis]
5 Qazi MA, Salim SK, Brown KR, Mikolajewicz N, Savage N, Han H, Subapanditha MK, Bakhshinyan D, Nixon A, Vora P, Desmond K, Chokshi C, Singh M, Khoo A, Macklin A, Khan S, Tatari N, Winegarden N, Richards L, Pugh T, Bock N, Mansouri A, Venugopal C, Kislinger T, Goyal S, Moffat J, Singh SK. Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma. Cell Rep 2022;40:111420. [PMID: 36170831 DOI: 10.1016/j.celrep.2022.111420] [Reference Citation Analysis]
6 Bulstrode H, Girdler GC, Gracia T, Aivazidis A, Moutsopoulos I, Young AMH, Hancock J, He X, Ridley K, Xu Z, Stockley JH, Finlay J, Hallou C, Fajardo T, Fountain DM, van Dongen S, Joannides A, Morris R, Mair R, Watts C, Santarius T, Price SJ, Hutchinson PJA, Hodson EJ, Pollard SM, Mohorianu I, Barker RA, Sweeney TR, Bayraktar O, Gergely F, Rowitch DH. Myeloid cell interferon secretion restricts Zika flavivirus infection of developing and malignant human neural progenitor cells. Neuron 2022:S0896-6273(22)00807-8. [PMID: 36174572 DOI: 10.1016/j.neuron.2022.09.002] [Reference Citation Analysis]
7 Johnson AL, Laterra J, Lopez-bertoni H. Exploring glioblastoma stem cell heterogeneity: Immune microenvironment modulation and therapeutic opportunities. Front Oncol 2022;12:995498. [DOI: 10.3389/fonc.2022.995498] [Reference Citation Analysis]
8 Chanoch-Myers R, Wider A, Suva ML, Tirosh I. Elucidating the diversity of malignant mesenchymal states in glioblastoma by integrative analysis. Genome Med 2022;14:106. [PMID: 36123598 DOI: 10.1186/s13073-022-01109-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wang R, Zhao L, Wang S, Zhao X, Liang C, Wang P, Li D. Regulatory pattern of abnormal promoter CpG island methylation in the glioblastoma multiforme classification. Front Genet 2022;13:989985. [DOI: 10.3389/fgene.2022.989985] [Reference Citation Analysis]
10 Mirzaei R, D’mello C, Liu M, Nikolic A, Kumar M, Visser F, Bose P, Gallo M, Yong VW. Single cell spatial analysis identifies regulators of brain tumor initiating cells.. [DOI: 10.1101/2022.09.13.507846] [Reference Citation Analysis]
11 Brooks LJ, Simpson Ragdale H, Hill CS, Clements M, Parrinello S. Injury programs shape glioblastoma. Trends Neurosci 2022:S0166-2236(22)00163-1. [PMID: 36089406 DOI: 10.1016/j.tins.2022.08.006] [Reference Citation Analysis]
12 Mirzaei R, Yong VW. Microglia-T cell conversations in brain cancer progression. Trends Mol Med 2022:S1471-4914(22)00211-8. [PMID: 36075812 DOI: 10.1016/j.molmed.2022.08.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Amoozgar Z, Ren J, Wang N, Andersson P, Ferraro GB, Krishnan S, Lei P, Subudhi S, Kawaguchi K, Tay RE, Gomes-santos IL, Huang P, Kim H, Fukumura D, Jain RK. Combined blockade of VEGF, Angiopoietin-2, and PD1 reprograms glioblastoma endothelial cells into quasi-antigen-presenting cells.. [DOI: 10.1101/2022.09.03.506476] [Reference Citation Analysis]
14 Tompa M, Kraboth Z, Galik B, Kajtar B, Gyenesei A, Kalman B. Epigenetic Suppression of the IL-7 Pathway in Progressive Glioblastoma. Biomedicines 2022;10:2174. [DOI: 10.3390/biomedicines10092174] [Reference Citation Analysis]
15 Chen X, Chen Y, Chen X, Wei P, Lin Y, Wu Z, Lin Z, Kang D, Ding C. Single-cell RNA sequencing reveals intra-tumoral heterogeneity of glioblastoma and a pro-tumor subset of tumor-associated macrophages characterized by EZH2 overexpression. Biochim Biophys Acta Mol Basis Dis 2022;:166534. [PMID: 36057370 DOI: 10.1016/j.bbadis.2022.166534] [Reference Citation Analysis]
16 Ruiz-moreno C, Salas SM, Samuelsson E, Brandner S, Kranendonk ME, Nilsson M, Stunnenberg HG. Harmonized single-cell landscape, intercellular crosstalk and tumor architecture of glioblastoma.. [DOI: 10.1101/2022.08.27.505439] [Reference Citation Analysis]
17 Picca A, Finocchiaro G. Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results. Curr Opin Oncol 2022. [PMID: 36000367 DOI: 10.1097/CCO.0000000000000895] [Reference Citation Analysis]
18 Yang X, Li Q. Pan-Cancer Analysis of the Oncogenic and Immunological Role of Solute Carrier Family 6 Member 8 (SLC6A8). Front Genet 2022;13:916439. [DOI: 10.3389/fgene.2022.916439] [Reference Citation Analysis]
19 Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov 2022. [PMID: 35974096 DOI: 10.1038/s41573-022-00520-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Wu M, Shi Y, Zhu L, Chen L, Zhao X, Xu C. Macrophages in Glioblastoma Development and Therapy: A Double-Edged Sword. Life (Basel) 2022;12:1225. [PMID: 36013403 DOI: 10.3390/life12081225] [Reference Citation Analysis]
21 Dai X, Shao Y, Tian X, Cao X, Ye L, Gao P, Cheng H, Wang X. Fusion between Glioma Stem Cells and Mesenchymal Stem Cells Promotes Malignant Progression in 3D-Bioprinted Models. ACS Appl Mater Interfaces 2022. [PMID: 35881920 DOI: 10.1021/acsami.2c06658] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Watchmaker PB, Colton M, Pineo-Cavanaugh PL, Okada H. Future development of chimeric antigen receptor T cell therapies for patients suffering from malignant glioma. Curr Opin Oncol 2022. [PMID: 35855503 DOI: 10.1097/CCO.0000000000000877] [Reference Citation Analysis]
23 Birocchi F, Cusimano M, Rossari F, Beretta S, Rancoita PMV, Ranghetti A, Colombo S, Costa B, Angel P, Sanvito F, Callea M, Norata R, Chaabane L, Canu T, Spinelli A, Genua M, Ostuni R, Merelli I, Coltella N, Naldini L. Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models. Sci Transl Med 2022;14:eabl4106. [DOI: 10.1126/scitranslmed.abl4106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Parmigiani E, Ivanek R, Rolando C, Hafen K, Turchinovich G, Lehmann FM, Gerber A, Brkic S, Frank S, Meyer SC, Wakimoto H, Günel M, Louvi A, Mariani L, Finke D, Holländer G, Hutter G, Tussiwand R, Taylor V, Giachino C. Interferon-γ resistance and immune evasion in glioma develop via Notch-regulated co-evolution of malignant and immune cells. Dev Cell 2022:S1534-5807(22)00446-4. [PMID: 35803280 DOI: 10.1016/j.devcel.2022.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Murota Y, Tabu K, Taga T. Cancer Stem Cell-Associated Immune Microenvironment in Recurrent Glioblastomas. Cells 2022;11:2054. [DOI: 10.3390/cells11132054] [Reference Citation Analysis]
26 Luo S, Yang G, Ye P, Cao N, Chi X, Yang WH, Yan X. Macrophages Are a Double-Edged Sword: Molecular Crosstalk between Tumor-Associated Macrophages and Cancer Stem Cells. Biomolecules 2022;12:850. [PMID: 35740975 DOI: 10.3390/biom12060850] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Gimple RC, Yang K, Halbert ME, Agnihotri S, Rich JN. Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity. Nat Rev Cancer 2022. [PMID: 35710946 DOI: 10.1038/s41568-022-00486-x] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
28 Ravi VM, Will P, Kueckelhaus J, Sun N, Joseph K, Salié H, Vollmer L, Kuliesiute U, von Ehr J, Benotmane JK, Neidert N, Follo M, Scherer F, Goeldner JM, Behringer SP, Franco P, Khiat M, Zhang J, Hofmann UG, Fung C, Ricklefs FL, Lamszus K, Boerries M, Ku M, Beck J, Sankowski R, Schwabenland M, Prinz M, Schüller U, Killmer S, Bengsch B, Walch AK, Delev D, Schnell O, Heiland DH. Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. Cancer Cell 2022;40:639-655.e13. [PMID: 35700707 DOI: 10.1016/j.ccell.2022.05.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
29 Kreatsoulas D, Bolyard C, Wu BX, Cam H, Giglio P, Li Z. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. J Hematol Oncol 2022;15:80. [PMID: 35690784 DOI: 10.1186/s13045-022-01298-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Varn FS, Johnson KC, Martinek J, Huse JT, Nasrallah MP, Wesseling P, Cooper LAD, Malta TM, Wade TE, Sabedot TS, Brat D, Gould PV, Wöehrer A, Aldape K, Ismail A, Sivajothi SK, Barthel FP, Kim H, Kocakavuk E, Ahmed N, White K, Datta I, Moon HE, Pollock S, Goldfarb C, Lee GH, Garofano L, Anderson KJ, Nehar-Belaid D, Barnholtz-Sloan JS, Bakas S, Byrne AT, D'Angelo F, Gan HK, Khasraw M, Migliozzi S, Ormond DR, Paek SH, Van Meir EG, Walenkamp AME, Watts C, Weiss T, Weller M, Palucka K, Stead LF, Poisson LM, Noushmehr H, Iavarone A, Verhaak RGW; GLASS Consortium. Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell 2022;185:2184-2199.e16. [PMID: 35649412 DOI: 10.1016/j.cell.2022.04.038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
31 Antonica F, Aiello G, Soldano A, Abballe L, Miele E, Tiberi L. Modeling Brain Tumors: A Perspective Overview of in vivo and Organoid Models. Front Mol Neurosci 2022;15:818696. [DOI: 10.3389/fnmol.2022.818696] [Reference Citation Analysis]
32 Pang L, Khan F, Heimberger AB, Chen P. Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma. Trends Cancer 2022:S2405-8033(22)00097-8. [PMID: 35624002 DOI: 10.1016/j.trecan.2022.04.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Chen N, Peng C, Li D. Epigenetic Underpinnings of Inflammation: A Key to Unlock the Tumor Microenvironment in Glioblastoma. Front Immunol 2022;13:869307. [PMID: 35572545 DOI: 10.3389/fimmu.2022.869307] [Reference Citation Analysis]
34 Zhao R, Pan Z, Li B, Zhao S, Zhang S, Qi Y, Qiu J, Gao Z, Fan Y, Guo Q, Qiu W, Wang S, Wang Q, Zhang P, Guo X, Deng L, Xue H, Li G. Comprehensive Analysis of the Tumor Immune Microenvironment Landscape in Glioblastoma Reveals Tumor Heterogeneity and Implications for Prognosis and Immunotherapy. Front Immunol 2022;13:820673. [PMID: 35309323 DOI: 10.3389/fimmu.2022.820673] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Marx S, Godicelj A, Wucherpfennig KW. A Conceptual Framework for Inducing T Cell-Mediated Immunity Against Glioblastoma. Semin Immunopathol 2022. [PMID: 35505129 DOI: 10.1007/s00281-022-00945-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Pang L, Khan F, Dunterman M, Chen P. Pharmacological targeting of the tumor–immune symbiosis in glioblastoma. Trends in Pharmacological Sciences 2022. [DOI: 10.1016/j.tips.2022.04.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Aldaz P, Martín-Martín N, Saenz-Antoñanzas A, Carrasco-Garcia E, Álvarez-Satta M, Elúa-Pinin A, Pollard SM, Lawrie CH, Moreno-Valladares M, Samprón N, Hench J, Lovell-Badge R, Carracedo A, Matheu A. High SOX9 Maintains Glioma Stem Cell Activity through a Regulatory Loop Involving STAT3 and PML. Int J Mol Sci 2022;23:4511. [PMID: 35562901 DOI: 10.3390/ijms23094511] [Reference Citation Analysis]
38 Salvalaggio A, Silvestri E, Sansone G, Pinton L, Magri S, Briani C, Anglani M, Lombardi G, Zagonel V, Della Puppa A, Mandruzzato S, Corbetta M, Bertoldo A. Magnetic Resonance Imaging Correlates of Immune Microenvironment in Glioblastoma. Front Oncol 2022;12:823812. [PMID: 35392230 DOI: 10.3389/fonc.2022.823812] [Reference Citation Analysis]
39 Kirschenbaum D, Amit I. Brain metastases: Not all tumors are created equal. Neuron 2022;110:1097-9. [PMID: 35390289 DOI: 10.1016/j.neuron.2022.03.027] [Reference Citation Analysis]
40 Zhao S, Xu B, Ma W, Chen H, Jiang C, Cai J, Meng X. DNA Damage Repair in Brain Tumor Immunotherapy. Front Immunol 2021;12:829268. [PMID: 35095931 DOI: 10.3389/fimmu.2021.829268] [Reference Citation Analysis]
41 Lospinoso Severini L, Bufalieri F, Infante P, Di Marcotullio L. Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors? Front Cell Dev Biol 2022;10:854352. [PMID: 35242765 DOI: 10.3389/fcell.2022.854352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Andersen JK, Miletic H, Hossain JA. Tumor-Associated Macrophages in Gliomas—Basic Insights and Treatment Opportunities. Cancers 2022;14:1319. [DOI: 10.3390/cancers14051319] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
43 Binder ZA, O'Rourke DM. Glioblastoma: The Current State of Biology and Therapeutic Strategies. Cancer Res 2022;82:769-72. [PMID: 35247893 DOI: 10.1158/0008-5472.CAN-21-3534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Wang Y, Yang C, Sims MM, Sacher JR, Raje M, Deokar H, Yue P, Turkson J, Buolamwini JK, Pfeffer LM. SS-4 is a highly selective small molecule inhibitor of STAT3 tyrosine phosphorylation that potently inhibits GBM tumorigenesis in vitro and in vivo. Cancer Lett 2022;:215614. [PMID: 35245627 DOI: 10.1016/j.canlet.2022.215614] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
45 Ravi VM, Neidert N, Will P, Joseph K, Maier JP, Kückelhaus J, Vollmer L, Goeldner JM, Behringer SP, Scherer F, Boerries M, Follo M, Weiss T, Delev D, Kernbach J, Franco P, Schallner N, Dierks C, Carro MS, Hofmann UG, Fung C, Sankowski R, Prinz M, Beck J, Salié H, Bengsch B, Schnell O, Heiland DH. T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. Nat Commun 2022;13:925. [PMID: 35177622 DOI: 10.1038/s41467-022-28523-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 14.0] [Reference Citation Analysis]
46 Uribe D, Niechi I, Rackov G, Erices JI, San Martín R, Quezada C. Adapt to Persist: Glioblastoma Microenvironment and Epigenetic Regulation on Cell Plasticity. Biology (Basel) 2022;11:313. [PMID: 35205179 DOI: 10.3390/biology11020313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
47 Yang T, Hu Y, Miao J, Chen J, Liu J, Cheng Y, Gao X. A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization. Acta Pharmaceutica Sinica B 2022;12:2658-71. [DOI: 10.1016/j.apsb.2022.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
48 Liu Y, Tu M, Wang L. Pan-Cancer Analysis Predicts FOXS1 as a Key Target in Prognosis and Tumor Immunotherapy. IJGM 2022;Volume 15:2171-85. [DOI: 10.2147/ijgm.s354195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Purshouse K, Friman ET, Boyle S, Dewari PS, Grant V, Hamdan A, Morrison GM, Brennan PM, Beentjes SV, Pollard SM, Bickmore WA. Oncogene expression from extrachromosomal DNA is driven by copy number amplification and does not require spatial clustering.. [DOI: 10.1101/2022.01.29.478046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Yang K, Shi Y, Luo M, Mao M, Zhang X, Chen C, Liu Y, He Z, Liu Q, Wang W, Luo C, Yin W, Wang C, Niu Q, Zeng H, Bian X, Ping Y. Identification of a unique tumor cell subset employing myeloid transcriptional circuits to create an immunomodulatory microenvironment in glioblastoma. OncoImmunology 2022;11:2030020. [DOI: 10.1080/2162402x.2022.2030020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
51 Mączyńska J, Raes F, Da Pieve C, Turnock S, Boult JKR, Hoebart J, Niedbala M, Robinson SP, Harrington KJ, Kaspera W, Kramer-marek G. Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy. BMC Med 2022;20. [DOI: 10.1186/s12916-021-02213-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
52 Malliou A, Kyritsis AP, Alexiou GA. Immunotherapeutic Strategies for Glioma Treatment. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_71] [Reference Citation Analysis]
53 Wu ZH, Yang DL, Wang L, Liu J. Epigenetic and Immune-Cell Infiltration Changes in the Tumor Microenvironment in Hepatocellular Carcinoma. Front Immunol 2021;12:793343. [PMID: 34925377 DOI: 10.3389/fimmu.2021.793343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Arrieta VA, Najem H, Petrosyan E, Lee-Chang C, Chen P, Sonabend AM, Heimberger AB. The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia. Int J Mol Sci 2021;22:13382. [PMID: 34948178 DOI: 10.3390/ijms222413382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
55 Alcantara Llaguno S, Parada LF. Cancer stem cells in gliomas: evolving concepts and therapeutic implications. Curr Opin Neurol 2021;34:868-74. [PMID: 34581301 DOI: 10.1097/WCO.0000000000000994] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Sun L, Lai TJ, Prins RM. Is there a role for neoadjuvant anti-PD-1 therapies in glioma? Curr Opin Neurol 2021;34:834-9. [PMID: 34608074 DOI: 10.1097/WCO.0000000000000992] [Reference Citation Analysis]
57 Zhong A, Chen T, Xing Y, Pan X, Shi M. FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer. Front Immunol 2021;12:758648. [PMID: 34745134 DOI: 10.3389/fimmu.2021.758648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Mirzaei R, Gordon A, Zemp FJ, Kumar M, Sarkar S, Luchman HA, Bellail AC, Hao C, Mahoney DJ, Dunn JF, Bose P, Yong VW. PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NFκB pathway. Sci Adv 2021;7:eabh2148. [PMID: 34739319 DOI: 10.1126/sciadv.abh2148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
59 Helal DO, Rouatbi N, Han S, Tzu-Wen Wang J, Walters AA, Abdel-Mottaleb MMA, Kamel AO, Geneidi AS, Awad GAS, Al-Jamal KT. A Natural Protein Based Platform for the Delivery of Temozolomide Acid to Glioma Cells. Eur J Pharm Biopharm 2021:S0939-6411(21)00262-9. [PMID: 34678408 DOI: 10.1016/j.ejpb.2021.10.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
60 Gao R, He B, Huang Q, Wang Z, Yan M, Wing-Fai Lam E, Lin S, Wang B, Liu Q. Cancer cell immune mimicry delineates onco-immunologic modulation. iScience 2021;24:103133. [PMID: 34632332 DOI: 10.1016/j.isci.2021.103133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
61 Khan S, Mahalingam R, Sen S, Martinez-Ledesma E, Khan A, Gandy K, Lang FF, Sulman EP, Alfaro-Munoz KD, Majd NK, Balasubramaniyan V, de Groot JF. Intrinsic Interferon Signaling Regulates the Cell Death and Mesenchymal Phenotype of Glioblastoma Stem Cells. Cancers (Basel) 2021;13:5284. [PMID: 34771447 DOI: 10.3390/cancers13215284] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
62 Landry AP, Samuel N, Spears J, Zador Z. Integrated computational analyses reveal novel insights into the stromal microenvironment of SHH-subtype medulloblastoma. Sci Rep 2021;11:20694. [PMID: 34667228 DOI: 10.1038/s41598-021-00244-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 He H, Huang J, Wu S, Jiang S, Liang L, Liu Y, Liu W, Xie L, Tao Y, Jiang Y, Cong L. The roles of GTPase-activating proteins in regulated cell death and tumor immunity. J Hematol Oncol 2021;14:171. [PMID: 34663417 DOI: 10.1186/s13045-021-01184-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
64 Borst K, Dumas AA, Prinz M. Microglia: Immune and non-immune functions. Immunity 2021;54:2194-208. [PMID: 34644556 DOI: 10.1016/j.immuni.2021.09.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 28] [Article Influence: 21.0] [Reference Citation Analysis]
65 Al-holou WN, Wang H, Ravikumar V, Oneka M, Verhaak RG, Kim H, Pratt D, Camelo-piragua S, Speers C, Wahl DR, Shankar S, Hollon T, Sagher O, Heth JA, Muraszko KM, Lawrence TS, de Carvalho AC, Mikkelsen T, Rao A, Rehemtulla A. Subclonal evolution and expansion of spatially distinct THY1-positive cells is associated with recurrence in glioblastoma.. [DOI: 10.1101/2021.09.10.459454] [Reference Citation Analysis]
66 Bufalieri F, Basili I, Di Marcotullio L, Infante P. Harnessing the Activation of RIG-I Like Receptors to Inhibit Glioblastoma Tumorigenesis. Front Mol Neurosci 2021;14:710171. [PMID: 34305530 DOI: 10.3389/fnmol.2021.710171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
67 Li YJ, Wu JY, Liu J, Qiu X, Xu W, Tang T, Xiang DX. From blood to brain: blood cell-based biomimetic drug delivery systems. Drug Deliv 2021;28:1214-25. [PMID: 34142628 DOI: 10.1080/10717544.2021.1937384] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
68 Dymova MA, Kuligina EV, Richter VA. Molecular Mechanisms of Drug Resistance in Glioblastoma. Int J Mol Sci 2021;22:6385. [PMID: 34203727 DOI: 10.3390/ijms22126385] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
69 Varn FS, Johnson KC, Wade TE, Malta TM, Sabedot TS, Barthel FP, Kim H, Ahmed N, Datta I, Barnholtz-sloan JS, Bakas S, D’angelo F, Gan HK, Garofano L, Huse JT, Khasraw M, Kocakavuk E, Migliozzi S, Ormond DR, Paek SH, Van Meir EG, Walenkamp AM, Watts C, Weller M, Weiss T, Wesseling P, Stead LF, Poisson LM, Noushmehr H, Iavarone A, Verhaak RG, The GLASS Consortium. Longitudinal analysis of diffuse glioma reveals cell state dynamics at recurrence associated with changes in genetics and the microenvironment.. [DOI: 10.1101/2021.05.03.442486] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
70 Güç E, Pollard JW. Redefining macrophage and neutrophil biology in the metastatic cascade. Immunity 2021;54:885-902. [PMID: 33979586 DOI: 10.1016/j.immuni.2021.03.022] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 35.0] [Reference Citation Analysis]
71 Liu I, Hack OA, Filbin MG. The imitation game: How glioblastoma outmaneuvers immune attack. Cell 2021;184:2278-81. [PMID: 33930294 DOI: 10.1016/j.cell.2021.04.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]